Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 2 (February)

1. Cancer proliferation gene discovery through functional genomics.
   Science, 319(5863): 620-4. [Abstract] [Full-text]
2. Profiling essential genes in human mammary cells by multiplex RNAi screening.
   Science, 319(5863): 617-20. [Abstract] [Full-text]
3. Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI.
   Br J Radiol, 81(962): 120-8. [Abstract] [Full-text]
4. Direct evidence for epithelial-mesenchymal transitions in breast cancer.
   Cancer Res, 68(3): 937-45. [Abstract] [Full-text]
5. Epitope landscape in breast and colorectal cancer.
   Cancer Res, 68(3): 889-92. [Abstract] [Full-text]
6. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
   Cancer Res, 68(3): 852-60. [Abstract] [Full-text]
7. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
   Cancer Res, 68(3): 826-33. [Abstract] [Full-text]
8. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition.
   Cancer Res, 68(3): 800-7. [Abstract] [Full-text]
9. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
   Cancer Res, 68(3): 767-76. [Abstract] [Full-text]
10. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases.
    Cancer Res, 68(3): 693-9. [Abstract] [Full-text]
11. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.
    Cancer Res, 68(3): 639-44. [Abstract] [Full-text]
12. Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples.
    Stat Appl Genet Mol Biol, 7: Article2. [Abstract] [Full-text]
13. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
    Future Oncol, 4(1): 125-31. [Abstract] [Full-text]
14. Molecular oncology: current trends in diagnostics.
    Future Oncol, 4(1): 61-70. [Abstract] [Full-text]
15. Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis.
    Future Oncol, 4(1): 23-39. [Abstract] [Full-text]
16. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
    Future Oncol, 4(1): 15-21. [Abstract] [Full-text]
17. Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells.
    Free Radic Biol Med, 44(4): 558-69. [Abstract] [Full-text]
18. Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG.
    Int J Cancer, 122(7): 1476-82. [Abstract] [Full-text]
19. Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells.
    Int J Cancer, 122(7): 1665-74. [Abstract] [Full-text]
20. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients.
    Int J Cancer, 122(7): 1557-66. [Abstract] [Full-text]
21. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts.
    Int J Cancer, 122(7): 1585-91. [Abstract] [Full-text]
22. Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
    Int J Cancer, 122(7): 1506-11. [Abstract] [Full-text]
23. Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma.
    J Cutan Pathol, 35(3): 332-6. [Abstract] [Full-text]
24. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing.
    J Natl Cancer Inst, 100(3): 218-21. [Abstract] [Full-text]
25. Personality factors and breast cancer risk: a 13-year follow-up.
    J Natl Cancer Inst, 100(3): 213-8. [Abstract] [Full-text]
26. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    J Natl Cancer Inst, 100(3): 207-12. [Abstract] [Full-text]
27. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.
    J Natl Cancer Inst, 100(3): 199-206. [Abstract] [Full-text]
28. BRCA1 regulates human mammary stem/progenitor cell fate.
    Proc Natl Acad Sci U S A, 105(5): 1680-5. [Abstract] [Full-text]
29. Under utilization of surveillance mammography among older breast cancer survivors.
    J Gen Intern Med, 23(2): 158-63. [Abstract] [Full-text]
30. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.
    Oncogene, 27(7): 1019-32. [Abstract] [Full-text]
31. Breast cancer mortality with varying invitational policies in organised mammography.
    Br J Cancer, 98(3): 641-5. [Abstract] [Full-text]
32. Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women.
    Br J Cancer, 98(3): 636-40. [Abstract] [Full-text]
33. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
    Br J Cancer, 98(3): 571-9. [Abstract] [Full-text]
34. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
    Genes Chromosomes Cancer, 47(4): 341-52. [Abstract] [Full-text]
35. The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas.
    Genes Chromosomes Cancer, 47(4): 299-308. [Abstract] [Full-text]
36. PPARalpha and PPARbeta are differentially affected by ethanol and the ethanol metabolite acetaldehyde in the MCF-7 breast cancer cell line.
    Toxicol Sci, 102(1): 120-8. [Abstract] [Full-text]
37. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    J Clin Oncol, 26(5): 814-9. [Abstract] [Full-text]
38. Research issues affecting preoperative systemic therapy for operable breast cancer.
    J Clin Oncol, 26(5): 806-13. [Abstract] [Full-text]
39. Advances in adjuvant endocrine therapy for postmenopausal women.
    J Clin Oncol, 26(5): 798-805. [Abstract] [Full-text]
40. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
    J Clin Oncol, 26(5): 791-7. [Abstract] [Full-text]
41. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
    J Clin Oncol, 26(5): 778-85. [Abstract] [Full-text]
42. Behavioral symptoms in patients with breast cancer and survivors.
    J Clin Oncol, 26(5): 768-77. [Abstract] [Full-text]
43. Implementing a survivorship care plan for patients with breast cancer.
    J Clin Oncol, 26(5): 759-67. [Abstract] [Full-text]
44. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    J Clin Oncol, 26(5): 736-44. [Abstract] [Full-text]
45. Clinical application of the 70-gene profile: the MINDACT trial.
    J Clin Oncol, 26(5): 729-35. [Abstract] [Full-text]
46. Development of the 21-gene assay and its application in clinical practice and clinical trials.
    J Clin Oncol, 26(5): 721-8. [Abstract] [Full-text]
47. Is there a role for positron emission tomography in breast cancer staging?
    J Clin Oncol, 26(5): 712-20. [Abstract] [Full-text]
48. Who should have breast magnetic resonance imaging evaluation?
    J Clin Oncol, 26(5): 703-11. [Abstract] [Full-text]
49. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases.
    J Clin Oncol, 26(5): 698-702. [Abstract] [Full-text]
50. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Ann Surg Oncol, 15(3): 691-703. [Abstract] [Full-text]
51. Factors associated with negative margins of lumpectomy specimen: potential use in selecting patients for intraoperative radiotherapy.
    Ann Surg Oncol, 15(3): 833-42. [Abstract] [Full-text]
52. Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
    Ann Surg Oncol, 15(3): 872-80. [Abstract] [Full-text]
53. The influence of age on the breast surgery decision-making process.
    Ann Surg Oncol, 15(3): 854-62. [Abstract] [Full-text]
54. S-classification of sentinel lymph node predicts axillary nonsentinel lymph node status in patients with breast cancer.
    Ann Surg Oncol, 15(3): 848-53. [Abstract] [Full-text]
55. Atypical ductal hyperplasia at margin of breast biopsy--is re-excision indicated?
    Ann Surg Oncol, 15(3): 843-7. [Abstract] [Full-text]
56. Video-assisted breast surgery and sentinel lymph node biopsy guided by three-dimensional computed tomographic lymphography.
    Surg Endosc, 22(2): 392-7. [Abstract] [Full-text]
57. Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
    Cancer Invest, 26(2): 159-67. [Abstract] [Full-text]
58. Differences in urinary incontinence between Hispanic and non-Hispanic white women: a population-based study.
    BJU Int, 101(5): 575-9. [Abstract] [Full-text]
59. Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment.
    Int J Radiat Oncol Biol Phys, 70(3): 916-20. [Abstract] [Full-text]
60. Three-dimensional intrafractional motion of breast during tangential breast irradiation monitored with high-sampling frequency using a real-time tumor-tracking radiotherapy system.
    Int J Radiat Oncol Biol Phys, 70(3): 931-4. [Abstract] [Full-text]
61. Sentinel node biopsy in larger or multifocal breast cancers: to do or not to do.
    ANZ J Surg, 78(3): 151-7. [Abstract] [Full-text]
62. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review.
    Br J Radiol, 81(963): 172-9. [Abstract] [Full-text]
63. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
    Oncogene, 27(8): 1095-105. [Abstract] [Full-text]
64. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
    Oncogene, 27(8): 1055-62. [Abstract] [Full-text]
65. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
    Oncogene, 27(8): 1036-44. [Abstract] [Full-text]
66. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    J Clin Oncol, 26(6): 925-33. [Abstract] [Full-text]
67. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
    J Clin Oncol, 26(6): 907-12. [Abstract] [Full-text]
68. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    J Clin Oncol, 26(6): 897-906. [Abstract] [Full-text]
69. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.
    Cancer Res, 68(4): 1003-11. [Abstract] [Full-text]
70. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Cancer Res, 68(4): 998-1002. [Abstract] [Full-text]
71. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
    Cancer Res, 68(4): 989-97. [Abstract] [Full-text]
72. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers.
    Cancer Res, 68(4): 971-5. [Abstract] [Full-text]
73. Numb chin syndrome: a nonmetastatic neurological manifestation of malignancy.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 105(3): e53-6. [Abstract] [Full-text]
74. Single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1alpha) gene in human sporadic breast cancer.
    Arch Med Res, 39(3): 338-45. [Abstract] [Full-text]
75. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
    Biochim Biophys Acta, 1783(3): 438-47. [Abstract] [Full-text]
76. Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).
    Hum Mutat, 29(3): 441-50. [Abstract] [Full-text]
77. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
    J Natl Cancer Inst, 100(4): 243-51. [Abstract] [Full-text]
78. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
    J Natl Cancer Inst, 100(4): 252-60. [Abstract] [Full-text]
79. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
    Am J Clin Pathol, 129(3): 383-90. [Abstract] [Full-text]
80. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive.
    Br J Surg, 95(3): 302-9. [Abstract] [Full-text]
81. Changing trends in the decision-making preferences of women with early breast cancer.
    Br J Surg, 95(3): 312-8. [Abstract] [Full-text]
82. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells.
    Oncogene, 27(9): 1320-6. [Abstract] [Full-text]
83. Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision.
    AJR Am J Roentgenol, 190(3): 637-41. [Abstract] [Full-text]
84. Papillary lesions of the breast diagnosed at percutaneous sonographically guided biopsy: comparison of sonographic features and biopsy methods.
    AJR Am J Roentgenol, 190(3): 630-6. [Abstract] [Full-text]
85. Intraoperative loss of core biopsy clips: clinical implications.
    AJR Am J Roentgenol, 190(3): W196-200. [Abstract] [Full-text]
86. A prospective comparison of continuous wound infiltration with ropivacaine versus single-injection paravertebral block after modified radical mastectomy.
    Anesth Analg, 106(3): 997-1001, table of contents. [Abstract] [Full-text]
87. Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast.
    Surgery, 143(3): 414-25. [Abstract] [Full-text]
88. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells.
    Biomed Microdevices, 10(2): 321-8. [Abstract] [Full-text]
89. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery.
    Biomed Microdevices, 10(2): 197-202. [Abstract] [Full-text]
90. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Jpn J Clin Oncol, 38(2): 99-105. [Abstract] [Full-text]
91. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
    Mol Carcinog, 47(3): 222-34. [Abstract] [Full-text]
92. Regulation of lamellipodia formation and cell invasion by CLIP-170 in invasive human breast cancer cells.
    Biochem Biophys Res Commun, 368(2): 199-204. [Abstract] [Full-text]
93. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
    Int J Cancer, 122(8): 1916-7. [Abstract] [Full-text]
94. Nitroxyl inhibits breast tumor growth and angiogenesis.
    Int J Cancer, 122(8): 1905-10. [Abstract] [Full-text]
95. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu.
    Int J Cancer, 122(8): 1722-9. [Abstract] [Full-text]
96. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.
    Int J Cancer, 122(8): 1832-41. [Abstract] [Full-text]
97. COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.
    BMC Cancer, 8: 36. [Abstract] [Full-text]
98. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.
    BMC Cancer, 8: 32. [Abstract] [Full-text]
99. Clinical and pathologic aspects of basal-like breast cancers.
    Nat Clin Pract Oncol, 5(3): 149-59. [Abstract] [Full-text]
100. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.
     Ann Oncol, 19(3): 496-500. [Abstract] [Full-text]
101. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
     Ann Oncol, 19(3): 487-95. [Abstract] [Full-text]
102. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
     J Clin Pathol, 61(3): 327-32. [Abstract] [Full-text]
103. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006.
     Ann Oncol, 19(3): 481-6. [Abstract] [Full-text]
104. Inflammatory breast cancer in Tunisia in the era of multimodality therapy.
     Ann Oncol, 19(3): 473-80. [Abstract] [Full-text]
105. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
     Ann Oncol, 19(3): 461-4. [Abstract] [Full-text]
106. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
     Ann Oncol, 19(3): 465-72. [Abstract] [Full-text]
107. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
     J Clin Pathol, 61(3): 317-21. [Abstract] [Full-text]
108. A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals.
     J Clin Pathol, 61(3): 278-82. [Abstract] [Full-text]
109. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells.
     Oncogene, 27(10): 1472-7. [Abstract] [Full-text]
110. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
     Oncogene, 27(10): 1461-71. [Abstract] [Full-text]
111. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
     Radiology, 246(3): 763-71. [Abstract] [Full-text]
112. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study.
     Radiology, 246(3): 734-41. [Abstract] [Full-text]
113. Mammographic distance as a predictor of nipple-areola complex involvement in breast cancer.
     Am J Surg, 195(3): 391-4; discussion 394-5. [Abstract] [Full-text]
114. Predicting cancer on excision of atypical ductal hyperplasia.
     Am J Surg, 195(3): 358-61; discussion 361-2. [Abstract] [Full-text]
115. Dedicated breast CT: initial clinical experience.
     Radiology, 246(3): 725-33. [Abstract] [Full-text]
116. Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)).
     FASEB J, 22(3): 671-81. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.